PROVECTUS BIOPHARMACEUTICALS, INC.
No SEC Form 4 filings for $PVCT in the last 30 days.
See all $PVCT insider activity →Provectus Biopharmaceuticals Inc. (PVCT) reported a second-quarter loss of $983,000, or less than 1 cent per share, according to the company. The report was generated using data from Zacks Investment Research and published by AP.
Provectus Biopharmaceuticals, Inc. said an SEC Schedule 13D amendment updates Edward Pershing’s stake. According to the filing, Pershing beneficially owns 52,441,275 common shares, 11.61%, via common holdings, Series D-1 preferred conversions, and exercisable options. The filing also details $7.5125M in convertible notes and recent note conversions/purchases.
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000315545 0000315545 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Over the past 7 days, alphai's AI scored 1 news story mentioning PVCT (PROVECTUS BIOPHARMACEUTICALS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent PVCT coverage spans corporate actions, earnings and financial news.
The article discloses a Q2 net loss figure, but provides no guidance, balance-sheet detail, or segment drivers.
The filing signals sustained insider-like accumulation and potential future dilution/overhang from conversion into common stock.
Board compensation is being settled via preferred stock conversion, implying near-term dilution/ownership changes for existing directors.
Share structure change authorization can affect liquidity, per-share pricing, and near-term trading dynamics; exact split ratio is left to the board.
alphai scores every news story that mentions PVCT with an AI model for sentiment and relevance, and aggregates insider trades from PROVECTUS BIOPHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Provectus Biopharmaceuticals Inc. (PVCT) reported a second-quarter loss of $983,000, or less than 1 cent per share, according to the company. The report was generated using data from Zacks Investment Research and published by AP.
1 min readProvectus Biopharmaceuticals, Inc. said an SEC Schedule 13D amendment updates Edward Pershing’s stake. According to the filing, Pershing beneficially owns 52,441,275 common shares, 11.61%, via common holdings, Series D-1 preferred conversions, and exercisable options. The filing also details $7.5125M in convertible notes and recent note conversions/purchases.
3 min readPROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000315545 0000315545 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readPROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0000315545 0000315545 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min read